From fat-loss fad to preventative medicine for a range of chronic health conditions that result from obesity and other metabolic conditions.

Over the last couple of weeks, I have received multiple requests for comment on a small speculative radiology software stock called 4D Medical (ASX: 4DX), in part because it announced on July 31, 2025 ...

Lovisa Holdings (ASX: LOV) delivered another year of strong global growth in FY 2025, setting the stage for further expansion going forward.

Currently, four analysts cover the stock (per Morningstar), and their median forecast is EPS of 27.7¢ in FY26 (vs 25.3¢ in FY25). Assuming no downgrades over the course of the year, that’s growth of ...

Why homelessness advocacy group Everybody's Home argues it makes sense, citing hundreds of millions in currently foregone tax revenue.

How to spot future large cap shares among ASX small caps. We cover key signals, a case study – PME vs NXT – and a potential ...

Vysarn shareholders will be looking for success in their nascent water division after solid but unexceptional FY 2025 results.

When I wrote about LaserBond (ASX:LBL) on July 14th for A Rich Life here, the share price was around 37 cents. At that time, I asked whether the market was undervaluing the business. I also pointed ...

Monash IVF (ASX: MVF) reported in FY25 results on Friday, showing a 6.7% increase in revenue vs FY24 to $271.9 million, and $25.7 million in net profit after tax (NPAT) vs a loss in FY24. The reported ...

Now, as bad as it seems, the above result was expected, and the market was well informed about it prior to these results, so I don’t think these numbers drove the share price decline from around $6 ...